Last reviewed · How we verify
Artesunate + Amodiaquine
Artesunate and amodiaquine work synergistically to kill malaria parasites by disrupting their hemoglobin metabolism and interfering with their DNA replication.
Artesunate and amodiaquine work synergistically to kill malaria parasites by disrupting their hemoglobin metabolism and interfering with their DNA replication. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax, ovale, and malariae.
At a glance
| Generic name | Artesunate + Amodiaquine |
|---|---|
| Also known as | ASAQ |
| Sponsor | Professor Anders Björkman |
| Drug class | Antimalarial combination |
| Target | Plasmodium falciparum hemoglobin metabolism and DNA synthesis |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Artesunate, an artemisinin derivative, generates reactive oxygen species that damage parasite proteins and DNA. Amodiaquine, a 4-aminoquinoline, inhibits heme detoxification in the parasite's digestive vacuole, causing toxic heme accumulation. Together, these complementary mechanisms reduce the risk of resistance development and provide rapid parasite clearance.
Approved indications
- Uncomplicated malaria caused by Plasmodium falciparum
- Malaria caused by Plasmodium vivax, ovale, and malariae
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Headache
- Dizziness
- Pruritus
Key clinical trials
- Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar (PHASE3)
- OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa (PHASE4)
- Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya
- A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines (PHASE3)
- A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs. (PHASE3)
- In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in Mozambique (PHASE4)
- Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 (PHASE2)
- Parasite Clearance and Protection from Infection (PCPI) in Cameroon (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Artesunate + Amodiaquine CI brief — competitive landscape report
- Artesunate + Amodiaquine updates RSS · CI watch RSS
- Professor Anders Björkman portfolio CI